Ginkgo Bioworks Holdings, Inc.’s DNA share price has surged by 14.49%, which has investors questioning if this is right time ...

Boston, MA – Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) recently reported a stock transaction by its Chief Financial Officer, Mark E. Dmytruk, according to a recent SEC filing. The transaction comes as ...

BOSTON—Steven P. Coen, the Chief Accounting Officer at Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), recently sold shares of the company's Class A Common Stock valued at approximately $4,933. The ...

Ginkgo Bioworks Holdings, Inc.’s DNA share price has dipped by 16.38%, which has investors questioning if this is right time to buy.

Short interest in Ginkgo Bioworks Holdings Inc (NYSE:DNA) increased during the last reporting period, rising from 7.37M to 7.83M. This put 23.51% of the company's publicly available shares short.

Therefore, the Zacks rating upgrade for Ginkgo Bioworks basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...